CAPRISA 012C / SAMBA trial III
Status:Ongoing
Phase:II
Principal Investigator(s):Salim S Abdool Karim
Objective:A double-blinded, randomized, placebo-controlled phase II trial to assess extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women
The CAPRISA 012C trial will evaluate the combination of CAP256V2LS and VRC07-523LS in young HIV-negative South African and Zambian women administered at 4-monthly and 6-monthly dosing intervals. The overall goal of the CAPRISA 012 trials is to develop a new, safe and effective long-acting HIV prevention technology principally for women, to alter the course of the HIV epidemic in Africa.
Last updated September 14, 2022
Prevention Option(s):Antibody Related Research
Study Design:Double-blind, Placebo-controlled, Randomized
Official Code:
PACTR202112683307570
Trial Sponsors:
EDCTP
Start Date
End Date
September 14, 2022
September 14, 2022
Enrollment:984
Age range:
18 Years ↔
30 Years
Population:Cisgender Women